INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|---|
Oct. 12, 2018 |
Aug. 20, 2018 |
Sep. 30, 2021 |
Sep. 30, 2020 |
Sep. 30, 2021 |
Sep. 30, 2020 |
|
| Naltrexone Implant Formulation [Member] | Trinity Compound Solutions [Member] | ||||||
| Cash paid for acquisition | $ 10,000 | |||||
| Aggregate purchase price, Shares | 20,000 | |||||
| Estimated useful lives | 5 years | |||||
| Aggregate purchase price, value | $ 236,000 | |||||
| Patents [Member] | ||||||
| Amortization expense | $ 295 | $ 294 | $ 884 | $ 878 | ||
| Accumulated amortization | 3,521 | 3,521 | ||||
| Intellectual Property [Member] | ||||||
| Amortization expense | 11,790 | $ 11,790 | 35,370 | $ 35,370 | ||
| Accumulated amortization | 94,520 | 94,520 | ||||
| Impairment loss | 141,480 | |||||
| Intellectual property, carrying value | $ 0 | $ 0 | ||||
| Six patent families [Member] | ||||||
| Estimated useful lives | 13 years | |||||
| Patent acquired cost | $ 15,200 | |||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|